Ebola epidemic in war-torn Democratic Republic of Congo, 2018: Acceptability and patient satisfaction of the recombinant Vesicular Stomatitis Virus – Zaire Ebolavirus Vaccine

Claude, Kasereka Masumbuko; Sawatzky, Julia; Hawkes, Michael

doi:10.1016/j.vaccine.2019.03.004

Cited by 27 publications

(27 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 The first emerging data from a small subset of 90 surveyed individuals vaccinated during the current EVD outbreak in the DRC seem to mirror the safety assessment obtained in these clinical trials, and while adverse events were frequent, arthralgia and rash were reported in only 7% and 5%, respectively. 42 Importantly, vaccine satisfaction was reported to be high, which is a very encouraging finding, as misconceptions about the vaccine and EVD constitute a serious challenge for health-care workers to administer vaccinations and care in the current outbreak setting.…”

Section: Safety Datamentioning

confidence: 82%

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

Fathi

Dahlke

Addo

2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The devastating Ebola virus (EBOV) outbreak in West Africa in 2013-2016 has flagged the need for the timely development of vaccines for high-threat pathogens. To be better prepared for new epidemics, the WHO has compiled a list of priority pathogens that are likely to cause future outbreaks and for which R&D efforts are, therefore, paramount (R&D Blueprint: https://www.who.int/blueprint/priority-diseases/en/). To this end, the detailed characterization of vaccine platforms is needed. The vesicular stomatitis virus (VSV) has been established as a robust vaccine vector backbone for infectious diseases for well over a decade. The recent clinical trials testing the vaccine candidate VSV-EBOV against EBOV disease now have added a substantial amount of clinical data and suggest VSV to be an ideal vaccine vector candidate for outbreak pathogens. In this review, we discuss insights gained from the clinical VSV-EBOV vaccine trials as well as from animal studies investigating vaccine candidates for Blueprint pathogens. ARTICLE HISTORY

show abstract

Section: Safety Datamentioning

confidence: 82%

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

Fathi

Dahlke

Addo

2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Analogous examples exist in which citizen compliance with public health recommendations was compromised by lack of trust in government authorities: vaccine hesitancy linked to government mistrust in the UK [25] and US [26] leading to measles outbreaks; HIV/AIDS in the US, which some Americans believed to be a “man-made weapon of racial warfare” [27]; and refusal of polio vaccine in Nigeria leading to a resurgence of cases in multiple neighboring countries [28]. With respect to vaccination, our own group has previously demonstrated a high level of satisfaction and broad community acceptability of the recombinant vesicular stomatitis virus-Zaire Ebolavirus (rVSV-ZEBOV) vaccine [29]. Any dissatisfaction centred around a preference for universal over ring vaccination and policies not to vaccinate vulnerable groups (e.g., pregnant women) [29].…”

Section: Discussionmentioning

confidence: 99%

“…With respect to vaccination, our own group has previously demonstrated a high level of satisfaction and broad community acceptability of the recombinant vesicular stomatitis virus-Zaire Ebolavirus (rVSV-ZEBOV) vaccine [29]. Any dissatisfaction centred around a preference for universal over ring vaccination and policies not to vaccinate vulnerable groups (e.g., pregnant women) [29].…”

Section: Discussionmentioning

confidence: 99%

Social resistance drives persistent transmission of Ebola virus disease in Eastern Democratic Republic of Congo: A mixed-methods study

2019

Self Cite

View full text Add to dashboard Cite

BackgroundThe second largest Ebola virus disease (EVD) epidemic in history is currently raging in Eastern Democratic Republic of Congo (DRC). Stubbornly persistent EVD transmission has been associated with social resistance, ranging from passive non-compliance to overt acts of aggression toward EVD reponse teams.MethodsWe explored community resistance using focus group discussions and assessed the prevalence of resistant views using standardized questionnaires.ResultsDespite being generally cooperative and appreciative of the EVD response (led by the government of DRC with support from the international community), focus group participants provided eyewitness accounts of aggressive resistance to control efforts, consistent with recent media reports. Mistrust of EVD response teams was fueled by perceived inadequacies of the response effort (“herd medicine”), suspicion of mercenary motives, and violation of cultural burial mores (“makeshift plastic morgue”). Survey questionnaires found that the majority of respondents had compliant attitudes with respect to EVD control. Nonetheless, 78/630 (12%) respondents believed that EVD was fabricated and did not exist in the area, 482/630 (72%) were dissatisfied with or mistrustful of the EVD response, and 60/630 (9%) sympathized with perpetrators of overt hostility. Furthermore, 102/630 (15%) expressed non-compliant intentions in the case of EVD illness or death in a family member, including hiding from the health authorities, touching the body, or refusing to welcome an official burial team. Denial of the biomedical discourse and dissatisfaction/mistrust of the EVD response were statistically significantly associated with indicators of social resistance.ConclusionsWe concluded that social resistance to EVD control efforts was prevalent among focus group and survey participants. Mistrust, with deep political and historical roots in this area besieged by chronic violence and neglected by the outside world, may fuel social resistance. Resistant attitudes may be refractory to short-lived community engagement efforts targeting the epidemic but not the broader humanitarian crisis in Eastern DRC.

show abstract

“…The rst step often begins with a pilot study, which explores the preliminary effectiveness, feasibility, and acceptability of treatments [2]. Acceptability in particular, is a key factor when designing and evaluating the success of treatment implementation, and is a strong predictor of patient satisfaction and trust, adherence, and health outcomes [3][4][5]. The term acceptability has been described many different ways but can be best de ned as a multifaceted construct that assesses whether providers and consumers of an intervention have a positive responseboth cognitively and emotionally -to a treatment [6].…”

Section: Introductionmentioning

confidence: 99%

“…Given that acceptability is a key predictor in determining success in future implementation and improving outcomes, [3][4][5] understanding whether programs like MBSGs are appealing to depressed adolescents is crucial. The objective of this secondary study was to investigate adolescents' perspectives on the acceptability of MBSGs as a depression treatment in primary care.…”

Section: Introductionmentioning

confidence: 99%

Do Adolescents Consider Mind-Body Skills Groups an Acceptable Treatment for Depression: Results from a Pilot Study.

Jones

Salgado

Aalsma

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Mind-Body Skills Groups (MBSGs) have shown promise in reducing adolescent depression symptoms; however, little is known about adolescents’ perspectives on this treatment. The objective of this study was to understand the acceptability of a new treatment for depressed adolescents in primary care settings. Methods: Adolescents participating in a 10-week MBSG treatment were interviewed to understand their perspectives on the acceptability and effectiveness of the treatment. Interviews were collected at post-intervention and at a 3-month follow-up visit. Results: A total of 39 adolescents completed both the post-intervention and 3-month follow-up interview. At post-intervention and follow-up, 84% of adolescents stated the MBSGs helped them. When asked how the MBSGs helped them, 3 areas were identified: learning new MBSG activities and skills, social connection with others within the group, and outcomes related to the group. Many adolescents reported no concerns with the MBSGs (49% at post- intervention; 62% at follow-up). Those with concerns identified certain activities as not being useful, wanting the group to be longer, and the time of group (after school) being inconvenient. Most adolescents reported that their life had changed because of the group (72% at post-intervention; 61% at follow-up), and when asked how, common responses included feeling less isolated and more hopeful. Conclusions: Adolescents found the MBSGs to be helpful and acceptable as a treatment option for depression in primary care. Given the strong emphasis on treatment preference autonomy and the social activities within the group, MBSGs appear well-suited for this age group. Trial Registration: NCT03363750

show abstract

Ebola epidemic in war-torn Democratic Republic of Congo, 2018: Acceptability and patient satisfaction of the recombinant Vesicular Stomatitis Virus – Zaire Ebolavirus Vaccine

Cited by 27 publications

References 10 publications

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens

Social resistance drives persistent transmission of Ebola virus disease in Eastern Democratic Republic of Congo: A mixed-methods study

Do Adolescents Consider Mind-Body Skills Groups an Acceptable Treatment for Depression: Results from a Pilot Study.

Contact Info

Product

Resources

About